Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) Equity Average: 2024-2025

Historic Equity Average for CG Oncology (CGON) over the last 2 years, with Sep 2025 value amounting to $679.0 million.

  • CG Oncology's Equity Average rose 24.69% to $679.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $679.0 million, marking a year-over-year increase of 24.69%. This contributed to the annual value of $305.1 million for FY2024, which is N/A change from last year.
  • As of Q3 2025, CG Oncology's Equity Average stood at $679.0 million, which was down 1.24% from $687.6 million recorded in Q2 2025.
  • CG Oncology's Equity Average's 5-year high stood at $719.1 million during Q1 2025, with a 5-year trough of $222.9 million in Q1 2024.
  • For the 2-year period, CG Oncology's Equity Average averaged around $578.4 million, with its median value being $635.1 million (2024).
  • Data for CG Oncology's Equity Average shows a peak YoY skyrocketed of 222.57% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows CG Oncology's Equity Average stood at $635.1 million in 2024, then increased by 24.69% to $679.0 million in 2025.
  • Its last three reported values are $679.0 million in Q3 2025, $687.6 million for Q2 2025, and $719.1 million during Q1 2025.